Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 28 04:00PM ET
15.54
Dollar change
+0.37
Percentage change
2.44
%
IndexRUT P/E- EPS (ttm)-2.65 Insider Own4.15% Shs Outstand59.32M Perf Week-4.01%
Market Cap921.83M Forward P/E- EPS next Y-3.16 Insider Trans-1.42% Shs Float56.85M Perf Month25.73%
Income-144.73M PEG- EPS next Q-0.65 Inst Own80.60% Short Float12.80% Perf Quarter30.81%
Sales80.89M P/S11.40 EPS this Y-7.80% Inst Trans-4.59% Short Ratio6.64 Perf Half Y149.84%
Book/sh3.43 P/B4.53 EPS next Y-10.49% ROA-42.39% Short Interest7.28M Perf Year59.71%
Cash/sh4.11 P/C3.78 EPS next 5Y- ROE-65.37% 52W Range4.22 - 18.12 Perf YTD50.58%
Dividend Est.- P/FCF- EPS past 5Y-59.00% ROI-75.94% 52W High-14.24% Beta2.16
Dividend TTM- Quick Ratio2.86 Sales past 5Y27.29% Gross Margin82.24% 52W Low268.25% ATR (14)1.12
Dividend Ex-Date- Current Ratio2.86 EPS Y/Y TTM24.89% Oper. Margin-194.51% RSI (14)56.13 Volatility7.06% 7.13%
Employees284 Debt/Eq0.17 Sales Y/Y TTM94.02% Profit Margin-178.93% Recom1.36 Target Price25.18
Option/ShortYes / Yes LT Debt/Eq0.13 EPS Q/Q-0.31% Payout- Rel Volume0.53 Prev Close15.17
Sales Surprise-3.20% EPS Surprise2.01% Sales Q/Q30.74% EarningsApr 10 BMO Avg Volume1.10M Price15.54
SMA208.19% SMA509.03% SMA20056.87% Trades Volume579,347 Change2.44%
Date Action Analyst Rating Change Price Target Change
Jun-26-23Resumed Oppenheimer Outperform $25
Mar-09-23Initiated Barclays Overweight $20
Feb-28-23Initiated Oppenheimer Outperform $25
Oct-11-22Initiated Morgan Stanley Equal-Weight $11
May-31-22Upgrade Wells Fargo Equal Weight → Overweight $25
Feb-10-22Initiated Wells Fargo Equal Weight $28
Dec-29-21Initiated H.C. Wainwright Buy $62
Oct-14-21Initiated SVB Leerink Outperform $50
Jun-04-21Resumed Robert W. Baird Outperform $45 → $46
Apr-30-21Resumed Piper Sandler Overweight $60
May-28-24 07:00AM
May-20-24 04:41PM
04:00PM
10:21AM
May-14-24 10:00AM
07:39AM Loading…
07:39AM
May-07-24 07:00AM
Apr-16-24 06:21PM
Apr-11-24 11:38PM
04:00PM
Apr-10-24 11:53AM
09:29AM
08:31AM
08:10AM
07:00AM
01:15PM Loading…
Apr-09-24 01:15PM
07:00AM
Apr-03-24 07:00AM
Apr-02-24 07:00AM
Mar-25-24 07:00AM
Mar-20-24 09:40AM
Mar-11-24 07:00AM
Mar-06-24 04:00PM
Mar-05-24 04:30PM
Feb-23-24 06:20AM
Feb-16-24 07:04PM
Feb-15-24 05:10PM
04:00PM
Feb-01-24 04:01PM
10:01AM
04:01PM Loading…
Jan-16-24 04:01PM
Jan-08-24 07:00AM
Jan-02-24 04:01PM
Dec-21-23 05:01PM
Dec-13-23 04:32PM
Dec-11-23 12:00PM
Dec-04-23 04:01PM
Nov-07-23 04:01PM
Nov-02-23 09:00AM
Nov-01-23 04:01PM
Oct-18-23 09:35AM
Oct-14-23 06:01AM
Oct-12-23 05:15PM
04:01PM
Oct-11-23 07:09AM
Oct-05-23 09:35AM
Oct-04-23 09:35AM
Sep-28-23 10:00AM
Sep-20-23 09:30AM
Sep-15-23 12:00PM
09:55AM
Sep-11-23 12:10PM
Sep-08-23 05:32AM
Sep-07-23 07:00AM
Aug-31-23 10:12PM
04:01PM
Aug-02-23 05:01AM
Jul-24-23 09:55AM
Jul-15-23 08:12AM
Jul-13-23 05:15PM
04:01PM
Jul-11-23 10:00AM
Jun-29-23 10:00AM
Jun-14-23 07:00AM
May-25-23 06:28AM
May-24-23 09:55AM
May-09-23 04:01PM
May-04-23 09:55AM
Apr-19-23 06:05AM
Apr-18-23 09:55AM
Apr-17-23 02:30PM
Apr-13-23 05:15PM
04:01PM
Apr-11-23 04:01PM
Mar-30-23 10:00AM
Mar-21-23 10:05AM
03:49AM
Mar-20-23 12:17PM
09:00AM
08:30AM
Mar-17-23 09:22AM
Mar-14-23 04:45PM
Mar-06-23 04:01PM
Feb-27-23 11:57AM
Feb-09-23 05:35PM
04:15PM
Feb-08-23 04:01PM
Jan-09-23 09:55AM
08:35AM
Jan-04-23 07:01AM
Dec-28-22 09:35AM
Dec-15-22 04:01PM
Dec-12-22 05:30PM
08:09AM
Dec-07-22 04:01PM
Nov-10-22 09:00AM
09:00AM
Nov-04-22 09:55AM
Nov-03-22 09:00AM
Nov-02-22 04:01PM
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rape, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
van Houte HansChief Financial OfficerMay 02 '24Sale12.833,49944,87868,333May 02 06:01 PM
Hansen GwennChief Scientific OfficerApr 30 '24Option Exercise0.005,206041,608Apr 30 06:33 PM
van Houte HansChief Financial OfficerApr 30 '24Option Exercise0.004,886073,219Apr 30 06:33 PM
Ring ChristineChief Legal OfficerApr 30 '24Option Exercise0.003,924021,351Apr 30 06:33 PM
Hansen GwennChief Scientific OfficerApr 30 '24Sale12.042,00724,16939,601Apr 30 06:33 PM
Ring ChristineChief Legal OfficerApr 30 '24Sale12.041,51318,22019,838Apr 30 06:33 PM
van Houte HansChief Financial OfficerApr 30 '24Sale12.041,38716,70371,832Apr 30 06:33 PM
van Houte HansChief Financial OfficerFeb 16 '24Sale10.026,81268,22368,333Feb 16 07:20 PM
van Houte HansChief Financial OfficerJan 30 '24Option Exercise0.004,886076,816Jan 30 06:53 PM
Hansen GwennChief Scientific OfficerJan 30 '24Option Exercise0.005,207038,736Jan 30 06:52 PM
Ring ChristineChief Legal OfficerJan 30 '24Option Exercise0.003,924019,187Jan 30 06:52 PM
Hansen GwennChief Scientific OfficerJan 30 '24Sale7.992,33418,64936,402Jan 30 06:52 PM
Ring ChristineChief Legal OfficerJan 30 '24Sale7.991,76014,06317,427Jan 30 06:52 PM
van Houte HansChief Financial OfficerJan 30 '24Sale7.991,67113,35275,145Jan 30 06:53 PM
van Houte HansChief Financial OfficerDec 20 '23Sale10.003,54135,42171,930Dec 21 05:19 PM
van Houte HansChief Financial OfficerDec 19 '23Sale10.0010,906109,09375,471Dec 20 04:55 PM
Hansen GwennChief Scientific OfficerOct 31 '23Sale5.201,6338,48733,529Nov 01 04:40 PM
Ring ChristineChief Legal OfficerOct 31 '23Sale5.201,2326,40315,263Nov 01 04:40 PM
van Houte HansChief Financial OfficerOct 31 '23Sale5.201,0805,61386,377Nov 01 04:41 PM
van Houte HansChief Financial OfficerOct 30 '23Option Exercise0.004,886087,457Nov 01 04:41 PM
Hansen GwennChief Scientific OfficerOct 30 '23Option Exercise0.005,207035,162Nov 01 04:40 PM
Ring ChristineChief Legal OfficerOct 30 '23Option Exercise0.003,924016,495Nov 01 04:40 PM
Hansen GwennChief Scientific OfficerJul 31 '23Sale9.651,88418,18929,955Aug 01 04:26 PM
Ring ChristineGeneral CounselJul 31 '23Sale9.651,42013,71012,544Aug 01 04:27 PM
van Houte HansChief Financial OfficerJul 31 '23Sale9.651,24512,02082,571Aug 01 04:28 PM
van Houte HansChief Financial OfficerJul 30 '23Option Exercise0.004,886083,816Aug 01 04:28 PM
Ring ChristineGeneral CounselJul 30 '23Option Exercise0.003,924013,964Aug 01 04:27 PM
Hansen GwennChief Scientific OfficerJul 30 '23Option Exercise0.005,207031,839Aug 01 04:26 PM